Genmab — November 2018
-
-
Kan være vi får nyt allerede på onsdag. Om morgenen offentliggøres LBA-titler. Hvis Maia (og Cassiopeia) er med, udsender Genmab sikkert en meddelelse herom. I den meddelelse kunne de passende oplyse om Janssen har søgt RTOR, og muligvis ved de allerede nu om det er bevilget.
-
Hvor meget hjælper d
et reelt hvis der er bevilget RTOR? Der er jo stadig mangel på infusionsstole! -
På CC talte han om split dosing som en overgang til sc, som allerede har hjulpet en del, og vil fortsætte at gøre det når det godkendes. infusion chair availability, Wimal, right now is a bottleneck for daratumumab. And then to bridge the time between now and the subcu co-formulation with high (inaudible) days, don't forget that Janssen has also filed for a split dosing of the first infusion.
-
that process is now going quite rapidly both in Europe and in the U.S., so we hope that we actually get quite quickly a label for the split dosing, and that's already helped, I think, to further boost the use of daratumumab, but the subcu will be a game changer, we believe.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind